Canada Life’s Akebia Therapeutics AKBA Stock Holding History

Canada Life’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-29,089	Closed	-$47K	–	1843
2025 Q4	$47K	Hold	29,089	–	–	﹤0.01%	1792
2025 Q3	$79K	Buy	+29,089	New	+$96.8K	﹤0.01%	1782
2022 Q2	–	Sell	-7,428	Closed	-$6K	–	2428
2022 Q1	$6K	Hold	7,428	–	–	﹤0.01%	2459
2021 Q4	$17K	Hold	7,428	–	–	﹤0.01%	2401
2021 Q3	$21K	Hold	7,428	–	–	﹤0.01%	2417
2021 Q2	$28K	Hold	7,428	–	–	﹤0.01%	2418
2021 Q1	$25K	Hold	7,428	–	–	﹤0.01%	2471
2020 Q4	$21K	Hold	7,428	–	–	﹤0.01%	2527
2020 Q3	$19K	Hold	7,428	–	–	﹤0.01%	2451
2020 Q2	$100K	Buy	7,428 +2,962	+66%	+$30.6K	﹤0.01%	2042
2020 Q1	$34K	Hold	4,466	–	–	﹤0.01%	2242
2019 Q4	$28K	Buy	+4,466	New	+$21.2K	﹤0.01%	2425
2019 Q3	–	Sell	-8,418	Closed	-$41K	–	1143
2019 Q2	$41K	Hold	8,418	–	–	﹤0.01%	2485
2019 Q1	$69K	Hold	8,418	–	–	﹤0.01%	2180
2018 Q4	$45K	Buy	8,418 +3,743	+80%	+$29.3K	﹤0.01%	2406
2018 Q3	$41K	Hold	4,675	–	–	﹤0.01%	2432
2018 Q2	$47K	Hold	4,675	–	–	﹤0.01%	2411
2018 Q1	$45K	Hold	4,675	–	–	﹤0.01%	2390
2017 Q4	$69K	Buy	+4,675	New	+$77.5K	﹤0.01%	2276

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Canada Life's AKBA Position: Q1 2026 in Review

Canada Life sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 29,089 shares — an estimated $47K sold.

Canada Life first reported a position in AKBA in Q4 2017 and held it in 19 quarters. The position peaked at $100K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Canada Life reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
Canada Life sold 29,089 Akebia Therapeutics shares in Q1 2026, an estimated $47K.
Canada Life first reported a position in Akebia Therapeutics in Q4 2017 and held it in 19 quarters.
Canada Life's Akebia Therapeutics position peaked at $100K in Q2 2020.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.